1. Home
  2. MCD vs NVO Comparison

MCD vs NVO Comparison

Compare MCD & NVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

MCD

McDonald's Corporation

HOLD

Current Price

$325.78

Market Cap

226.8B

ML Signal

HOLD

Logo Novo Nordisk A/S

NVO

Novo Nordisk A/S

HOLD

Current Price

$49.33

Market Cap

269.6B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MCD
NVO
Founded
1940
1923
Country
United States
Denmark
Employees
N/A
N/A
Industry
Restaurants
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
226.8B
269.6B
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
MCD
NVO
Price
$325.78
$49.33
Analyst Decision
Buy
Hold
Analyst Count
24
10
Target Price
$333.09
$54.25
AVG Volume (30 Days)
3.1M
27.8M
Earning Date
02-11-2026
02-04-2026
Dividend Yield
2.27%
2.58%
EPS Growth
2.90
1.77
EPS
11.72
3.62
Revenue
$26,264,000,000.00
$48,588,245,669.00
Revenue This Year
$3.98
$1.02
Revenue Next Year
$5.84
$6.81
P/E Ratio
$27.92
$12.90
Revenue Growth
1.25
6.43
52 Week Low
$283.47
$43.08
52 Week High
$328.06
$93.80

Technical Indicators

Market Signals
Indicator
MCD
NVO
Relative Strength Index (RSI) 67.81 40.62
Support Level $321.24 $43.24
Resistance Level $328.06 $64.16
Average True Range (ATR) 4.72 2.26
MACD 1.66 -1.91
Stochastic Oscillator 87.78 29.78

Price Performance

Historical Comparison
MCD
NVO

About MCD McDonald's Corporation

McDonald's is the world's largest restaurant brand, with nearly $131 billion in systemwide sales across more than 44,000 restaurants and over 100 markets. The quick-service chain built its early reputation on speed, consistency, and affordable hamburgers, and today its global menu spans burgers, chicken, breakfast, and beverages that have helped popularize American fast-food cuisine worldwide. The firm derives the bulk of its revenue from franchise royalties and rent (about 61%), with the remainder stemming from company-operated restaurants across three segments: the United States (41% of systemwide sales), international operated markets (34%), and international developmental/licensed markets (25%).

About NVO Novo Nordisk A/S

With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.

Share on Social Networks: